1 tracked superinvestor hold Novartis AG (NVS), worth $667M combined, led by PRIMECAP team. Smart money is accumulating NVS as of the latest 13F filings.
Current price
$159.99
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$667M
disclosed long exposure
Tier-1 conviction
0
concentrated holders
Net this quarter
+1
1 buying · 0 selling
Smart money is net accumulating NVS: 1 funds added or opened versus 0 trimming. 1 opened a brand-new position.
Novartis AG (NVS) appears mainly in diversified and quant books here (1 funds, $667M combined) rather than in concentrated conviction portfolios — read the holders below with that in mind.
The largest position belongs to PRIMECAP team at 0.7% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
This quarter 1 fund opened a brand-new position (PRIMECAP team), with 0 adding and 0 trimming — a net accumulation signal.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| New buy | 0.7% | $667M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own NVS?
1 tracked funds hold Novartis AG (NVS), the largest being PRIMECAP team (Vanguard PRIMECAP) at 0.7% of its 13F portfolio. 0 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling NVS?
In the most recent 13F quarter, 1 tracked fund added or opened NVS and 0 trimmed it, including 1 brand-new position.
How much NVS do tracked funds hold?
Combined disclosed long exposure to NVS across tracked superinvestors is $667M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.